Text Size
35 studies found for:    (weekly paclitaxel OR dose dense paclitaxel) AND ovarian cancer | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Conditions: Ovarian Carcinoma;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel;   Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
2 Recruiting Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: paclitaxel;   Drug: pazopanib
3 Recruiting A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Conditions: Solid Tumors;   Ovarian Cancer
Interventions: Drug: OSI-906;   Drug: Paclitaxel
4 Recruiting Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Conditions: Ovarian Cancer;   Endometrial Cancer;   Uterine Cervical Cancer
Interventions: Drug: Filgrastim;   Drug: Paclitaxel;   Drug: Carboplatin
5 Recruiting First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
6 Recruiting [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: Pazopanib and paclitaxel
7 Recruiting EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100;   Drug: Paclitaxel
8 Recruiting Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Condition: Ovarian Neoplasms
Intervention: Drug: Vorinostat
9 Not yet recruiting Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Conditions: Breast Cancer;   Ovarian Cancer;   Gynecological Cancer;   Head and Neck Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Non-squamous Cell Lung Cancer
Intervention: Drug: PM01183 + paclitaxel +/- bevacizumab
10 Recruiting A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Condition: Platinum Resistant Ovarian Cancer
Intervention: Drug: Paclitaxel
11 Recruiting Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)
Condition: Ovarian Sex-cord Stromal Tumor
Interventions: Drug: Paclitaxel;   Drug: Bevacizumab
12 Not yet recruiting VB-111+Paclitaxel for Recurrent Mullerian Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Malignant Tumor of Peritoneum;   Papillary Carcinoma of Uterus;   Uterine Malignant Mixed Muellerian Tumour
Intervention: Drug: Paclitaxel
13 Recruiting ICON8: Weekly Chemotherapy in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel
14 Unknown † A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Paclitaxel, Carboplatin and Vorinostat
15 Recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Procedure: neoadjuvant therapy;   Procedure: adjuvant therapy;   Procedure: therapeutic conventional surgery;   Procedure: computed tomography
16 Recruiting A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor
Conditions: Advanced Solid Tumors;   Advanced Recurrent Ovarian Tumors
Interventions: Drug: MEDI3617;   Drug: MEDI3617 + Bev Q3W Dose Escalation;   Drug: MEDI3617 + Bev Q2W Dose Escalation;   Drug: MEDI3617 + Bev Optional Dose Expansion;   Drug: MEDI3617 + Weekly Pax Dose Escalation;   Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc;   Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc;   Drug: Advanced Recurrent Ovarian Tumors
17 Recruiting Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Drug: paclitaxel
18 Recruiting Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus;   Drug: paclitaxel
19 Recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: cabozantinib-s-malate;   Drug: paclitaxel;   Other: laboratory biomarker analysis
20 Recruiting Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Uterine Cancer
Interventions: Drug: Olaparib;   Drug: Carboplatin;   Drug: Paclitaxel
To Top

Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results
† Indicates status has not been verified in more than two years